A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients

Rasmussen, Alice; Lunde, Marianne; Sørensen, Keld E.; Qvitzau, Susanne; Bech, Per

doi:10.1016/s0924-977x(02)80275-9

Cited by 33 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sertraline is the secondmost studied SSRI in both treatment and prevention of PSD. Two separate sertraline studies did not differentiate from placebo [32,33]. Of two separate prevention studies, one study did not differentiate from placebo, but the other prevented depressive symptoms compared with placebo [34].…”

Section: Evidence-based Pharmacotherapy Of Psdmentioning

confidence: 99%

Recent advances in poststroke depression

Tharwani¹,

Yerramsetty²,

Mannelli³

et al. 2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

Depression is the most common psychiatric complication after stroke. Its prevalence varies from 20% to 80%, and it is underdiagnosed and undertreated. It has significant impact on rehabilitation, motor recovery, activities of daily living, social and interpersonal life, and mortality. Several studies have shown that biological and psychosocial factors play significant roles in the development of this disabling disease. Recent research shows that neurochemical processes also may play some role in the pathophysiology of this condition. Several trials have shown evidence that the older, as well as newer antidepressants and psychostimulants may reduce/prevent depressive symptoms after stroke. At this point there are no clear guidelines available to choose safe and effective treatments. Drugs are selected based on their efficacy and side effect profile in these patients. More research is needed to understand the pathophysiology of depression after stroke. There also is a need for more randomized clinical trials to better treat patients with this condition.

show abstract

Section: Evidence-based Pharmacotherapy Of Psdmentioning

confidence: 99%

Recent advances in poststroke depression

Tharwani¹,

Yerramsetty²,

Mannelli³

et al. 2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…Thus medication clinical trials in humans are confounded by the differences in the underlying disease presenting as PSD. In two double blind, placebo controlled studies sertraline was no better than placebo in treatment or prevention of PSD [23,24]. Of the SSRIs studied in the treatment of this illness, citalopram has been shown to have the most benefit in the treatment of PSD demonstrated by symptom reduction on the Beck Depression Inventory Scale [25,26].…”

Section: Treatment Of Post-stroke Depressionmentioning

confidence: 99%

Post Stroke Depression: Treatments and Complications in a Young Adult

Capaldi

Wynn

2009

Psychiatr Q

View full text Add to dashboard Cite

Post-stroke depression has been noted to be one of the most frequent complications of stroke with an estimated prevalence of as high as 80%. However, the incidence of stroke in the young is extremely low and evidence based therapy for this complication is quite limited. The case of a 28-year-old woman who experienced a basilar artery vasospasmic stroke resulting in anoxic brain injury to the midbrain and paramedian thalamus is presented, along with a literature review of psychiatric complications of this injury to include post-stroke depression (PSD). Therapeutic modalities such as TCAs, SSRIs, atypical antipsychotics and stimulant medications are also reviewed as these medications may aid in the treatment of such patients but may also contribute to psychiatric sequelae.

show abstract

“…10 in der Behandlungsgruppe senkte [65]. Eine weitere Studie, die über 12 Wochen ebenfalls doppelblind Nortriptylin mit Fluoxetin und Plazebo verglich, zeigte bei initial nicht depressiven Poststroke-Patienten eine signifikante Verringerung depressiver Symptome, die sich in der Folge entwickelten [50].…”

Section: Prophylaktische Therapie Bereits In Der Akutphase?unclassified

Poststroke-Depression

Kronenberg

Katchanov²,

Endres³

2006

Nervenarzt

View full text Add to dashboard Cite

Post-stroke depression (PSD) is the most frequent psychiatric complication following ischemic stroke, affecting up to 50% of all such patients. Moreover, PSD is associated with increased morbidity and mortality following ischemic stroke. In clinical practice, PSD is underdiagnosed and many affected patients do not receive adequate treatment. This review article summarizes current knowledge regarding epidemiogy, clinical features, risk factors and predisposition, therapy, and prophylaxis of PSD.

show abstract

A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients

Cited by 33 publications

References 0 publications

Recent advances in poststroke depression

Recent advances in poststroke depression

Post Stroke Depression: Treatments and Complications in a Young Adult

Poststroke-Depression

Contact Info

Product

Resources

About